Investors should consider Micron Technology (MU) a high-conviction "buy the dip" opportunity, as memory remains a critical, undersupplied pillar of the AI infrastructure trade. In the biotech sector, Abivax (ABVX) is a strong long play due to "best-in-disease" efficacy for its Ulcerative Colitis drug, which positions the company as a potential $5 billion acquisition target for giants like Eli Lilly. Conversely, Sellas Life Sciences (SLS) is identified as a high-conviction short, with expectations that its upcoming clinical trial will fail completely because it cannot outperform modern standard-of-care results. Rocket Lab (RKLB) is also a short candidate, as its recent acquisition news is viewed as overhyped and its current valuation is unsustainable relative to its low-margin government contract business. Finally, for those with high risk tolerance, Evomune presents a contrarian buying opportunity following a stock crash, as the market is currently assigning zero value to its promising IL-18 drug pipeline.

NVIDIA (NVDA)

• Shkreli argues against the common perception of NVIDIA, stating, "NVIDIA is not a hardware company," implying its value lies deeper in its software stack and ecosystem, despite others' insistence that it is hardware because "you can hold it."

Takeaways

• Investors should look beyond the physical chips and evaluate NVIDIA’s software and AI integration as its primary competitive advantage.

Rocket Lab (RKLB)

• Sentiment: Bearish / Short
• Shkreli expressed strong skepticism regarding Rocket Lab’s acquisition of Iridium, calling the deal "cheesy" and questioning the "historic" nature of the headline.
• He characterized the space sector as "hype and no substance" and a "cheesy sector."
• Financials: Noted that while revenue was higher than his model ($200M vs. $168M), the business remains "low-margin" and "lumpy" with heavy reliance on government contracts (NASA).
• Market Cap: Questioned the $52 billion valuation (note: transcript mentions 52B, though current market caps may vary) relative to its $1B revenue run rate.

Takeaways

• Action: Shkreli opened a short position on Rocket Lab, specifically "fading" the spike from the Iridium news.
• Risk Factor: The "Space" sector is prone to hype; high competition from players like SpaceX and Bezos (Blue Origin) makes it a difficult business environment.

Micron Technology (MU)

• Sentiment: Bullish
• Shkreli is Long Micron, noting significant "memory news" and Intel's potential entry into the DRAM/memory game.
• He dismissed concerns regarding new Chinese manufacturers (CXMT), citing analysts who claim they cannot even meet domestic Chinese demand.

Takeaways

• Action: Shkreli is Long and advised "BTFD" (Buy the F***ing Dip) when the stock showed weakness during the stream.
• Insight: Memory remains a critical pillar of the AI trade, and supply concerns from China appear overblown.

Evamune (Private/Biotech) / Evomune

• Sentiment: Bullish (Contrarian)
• The stock dropped ~31% following the failure of a Phase 2b trial.
• Shkreli's thesis: The failed drug was "well-known to be likely to fail," and the market is ignoring their IL-18 drug, which he describes as a "brand new mechanism" and a "generational opportunity."

Takeaways

• Action: Shkreli bought 5,000 shares (or equivalent position) of the "fallen knife," betting that the removal of the failed asset allows the market to eventually value the promising IL-18 pipeline.

Sellas Life Sciences (SLS)

• Sentiment: Strongly Bearish / Short
• Shkreli predicts the Regal clinical trial will be a "zero" and a "failure."
• He argues that the "long" thesis (that the trial is taking a long time because patients are living longer) is a classic biotech amateur mistake.
• Thesis: Overall survival (OS) in AML (Acute Myeloid Leukemia) has improved generally in the medical field, meaning the "control" group is likely living longer, which will cause the trial to fail to show a statistical benefit for the drug.

Takeaways

• Action: Shkreli is looking to short SLS aggressively, calling it a "scam" and an "obvious zero."
• Risk: High short interest (30%) makes it a "crowded" trade and prone to volatility, but Shkreli maintains the drug "can't work" pharmacologically.

Abivax (ABVX)

• Sentiment: Bullish
• Discussion centered on the Abtech Part 2 data release for Obefazimod in Ulcerative Colitis (UC).
• Efficacy: Reported "best-in-disease" efficacy in highly refractory patients.
• Safety: Addressed concerns over malignancies/skin cancers. Shkreli and guest KOLs argued that the rates are within the "background range" for UC patients and do not suggest a drug-induced signal.

Takeaways

• Action: Shkreli is Long ABVX, viewing the safety data as "reassuring" and the efficacy as "unmatched."
• Insight: The drug could potentially reach $5 billion in revenue if approved, making it a major M&A target for companies like J&J or Eli Lilly.

Investment Themes & Sector Insights

Biotech "Binary Events"

• Shkreli warns against "NPC thinking" in biotech—specifically the idea that a long trial duration equals success. He cites historical failures like Oncothyreon and Cassava as warnings.

The "Bag 7" vs. "Magnificent 7"

• A play on the "Magnificent 7," Shkreli refers to "Bag 7" stocks that retail investors are "holding the bag" on, though specific names were mostly implied through his bearishness on speculative tech/space.

Software & AI Infrastructure

• Intel (INTC): Mentioned as potentially entering the memory market, which could be a pivot to watch.
• Comcast (CMCSA): Noted the spinning off of NBCUniversal as a "really big deal" and a positive move by the Roberts family.
• Quantum Computing: Shkreli remains a skeptic on the "practical milestones" of quantum computing, viewing it as a scientific milestone but a "short" for current investment purposes (D-Wave, IonQ).